Compare MXCT & PMI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MXCT | PMI |
|---|---|---|
| Founded | 1999 | 1981 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 186.7M | 202.7M |
| IPO Year | 2021 | 2025 |
| Metric | MXCT | PMI |
|---|---|---|
| Price | $1.47 | $3.05 |
| Analyst Decision | Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $7.50 | N/A |
| AVG Volume (30 Days) | 1.5M | ★ 2.3M |
| Earning Date | 11-12-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $34,419,000.00 | $4,767,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $10.69 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 8.81 |
| 52 Week Low | $1.26 | $1.90 |
| 52 Week High | $5.20 | $13.68 |
| Indicator | MXCT | PMI |
|---|---|---|
| Relative Strength Index (RSI) | 41.45 | N/A |
| Support Level | $1.45 | N/A |
| Resistance Level | $1.80 | N/A |
| Average True Range (ATR) | 0.12 | 0.00 |
| MACD | -0.02 | 0.00 |
| Stochastic Oscillator | 14.42 | 0.00 |
MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The Company has one reportable segment, cell engineering technology. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies.
Picard Medical Inc operates through its wholly owned subsidiary, a medical technology company focused on developing, manufacturing, and commercializing an implantable Total Artificial Heart. It is engaged in designing, manufacturing, producing, supplying, marketing, and selling medical device products, including TAH. The TAH is an implantable system designed to assume the full function of a failed human heart in patients suffering from advanced heart failure.